Navigating challenges in human pluripotent stem cell-derived islet therapy for type 1 diabetes

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Endocrinology

Background:

• Human pluripotent stem cells (hPSCs) are used to generate tissues for disease modeling, drug testing, and cell replacement therapies.
• Pancreatic cell therapies derived from hPSCs have entered clinical trials for type 1 diabetes (T1D) treatment since 2014.
• Early trials showed encouraging results, including C-peptide detection, despite initial challenges.

Purpose of the Study:

• To review recent and emerging advances in hPSC-derived pancreatic cell therapies for type 1 diabetes.
• To discuss improvements in cell product, engraftment, and immunomodulation strategies.
• To evaluate the potential, risks, and clinical scalability of these experimental models.

Main Methods:

• Review of recent clinical trials and research in hPSC-derived pancreatic cell therapies.
• Categorization of advancements into cell product improvement, engraftment promotion, and immunomodulation.
• Analysis of therapeutic efficacy, longevity, and transplantation microenvironment factors.

Main Results:

• Recent clinical trials demonstrate success in reducing or eliminating exogenous insulin administration for T1D patients.
• Advances in cell differentiation and delivery technologies enhance therapeutic efficacy.
• Improved understanding of the transplantation microenvironment supports cell survival and function.

Conclusions:

• hPSC-derived pancreatic cell therapies offer significant hope for a type 1 diabetes cure via regenerative medicine.
• Ongoing research focuses on optimizing cell products, engraftment, and immune tolerance.
• Translating these experimental models to widespread clinical application requires careful consideration of potential, risks, and scalability.